Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients
By Heloisa Sawaya, I. Sebag, J. Plana, J. Januzzi, B. Ky, V. Cohen, Sucheta Gosavi, J. Carver, S. Wiegers, Randolph P. Martin and 6 more. American Journal of Cardiology, 2011
683 citations recorded by the source corpus.
As breast cancer survival increases, cardiotoxicity associated with chemotherapeutic regimens such as anthracyclines and trastuzumab becomes a more significant issue. Assessment of the left ventricular (LV) ejection fraction fails to detect subtle alterations in LV function. The objective of this study was to evaluate whether more sensitive echocardiographic measurements and biomarkers could predict future cardiac dysfunction in chemotherapy-treated patients. Forty-three patients diagnosed with breast cancer who received anthracyclines and trastuzumab therapy underwent echocardiography and blood sampling at 3 time points (baseline and 3 and 6 months during the course of chemotherapy). The LV ejection fraction; peak systolic myocardial longitudinal, radial, and circumferential strain; echocardiographic markers of diastolic function; N-terminal pro–B-type natriuretic peptide; and high-sensitivity cardiac troponin I were measured. Nine patients (21%) developed cardiotoxicity (1 at 3 months and 8 at 6 months) as defined by the Cardiac Review and Evaluation Committee reviewing trastuzumab. A decrease in longitudinal strain from baseline to 3 months and detectable high-sensitivity cardiac troponin I at 3 months were independent predictors of the development of cardiotoxicity at 6 months. The LV ejection fraction, parameters of diastolic function, and N-terminal pro–B-type natriuretic peptide did not predict cardiotoxicity. In conclusion, cardiac troponin plasma concentrations and longitudinal strain predict the development of cardiotoxicity in patients treated with anthracyclines and trastuzumab. The 2 parameters may be useful to detect chemotherapy-treated patients who may benefit from alternative therapies, potentially decreasing the incidence of cardiotoxicity and its associated morbidity and mortality.
Subfields: Cardiology and Cardiovascular Medicine, Oncology, Polymers and Plastics
View Paper: https://www.semanticscholar.org/paper/b2ee6a81e97bddaa222c53ad42162fe54e81ccca
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Oncology
Citations in the corpus
- Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, methodology): “A predictive value of regional strain was also reported in smaller studies with shorter follow-up periods.(153,156,159) Importantly, although the decrease in longitudinal strain and LVEF appears to at least partially persist throughout the duration of the treatment,(160) it is unknown what their evo”
- 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, neutral): “evaluating these interventions are mixed (83-86).”
- Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, methodology): “The prognostic value of early measurement of systolic deformation indices in the prediction of subsequent LV systolic function has been evaluated in several studies, both in animals(6) and humans.(153,156,159,160) In 81 patients with breast cancer treated with anthracyclines followed by taxanes and ”
- 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “The use of advanced echocardiographic techniques or biomarkers to identify increased HF risk in those receiving chemotherapy may be useful but remain unvalidated as yet (333).”
- Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. (2014, background): “2011 (41) STE Breast 43 49 10 100 Doxorubicin,”
- Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. (2014, methodology): “Echocardiographic strain imaging has recently emerged as a promising method for detection of cardiotoxicity prior to LV dysfunction (57).”